New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 5, 2017 – The FDA announced the approval of Mitsubishi Tanabe Pharma Corporation’s Radicava (edaravone) injection for the treatment of amyotrophic lateral sclerosis (ALS).
Download PDF
Return to publications
